Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 35

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
Edesa Biotech, Inc.

Condensed Interim Consolidated Balance Sheets

			December 31, 2024

			September 30, 2024

			Audited

			Assets:

			Current assets:

			Cash and cash equivalents

			$
			1,563,502

			$
			1,037,320

			Accounts and other receivable

			350,639

			270,908

			Prepaid expenses and other current assets

			157,787

			367,394

			Total current assets

			2,071,928

			1,675,622

			Non-current assets:

			Long-term deposits

			38,698

			41,151

			Intangible asset, net

			2,053,555

			2,078,848

			Right-of-use assets

			-

			18,361

			Total assets

			$
			4,164,181

			$
			3,813,982

			Liabilities and shareholders' equity:

			Current liabilities:

			Accounts payable and accrued liabilities

			$
			1,900,219

			$
			1,812,960

			Short-term right-of-use lease liabilities

			-

			19,867

			Total current liabilities

			1,900,219

			1,832,827

			Shareholders' equity:

			Capital shares

			Authorized unlimited common and preferred shares without par value

			Issued and outstanding:

			3,467,658 common shares (September 30, 2024 - 3,247,389)

			47,562,091

			47,236,024

			150 Series A-1 preferred shares (September 30, 2024 - 0)

			981,174

			-

			Additional paid-in capital

			14,176,399

			13,576,757

			Accumulated other comprehensive loss

			(223,957
			)

			(242,613
			)

			Accumulated deficit

			(60,231,745
			)

			(58,589,013
			)

			Total shareholders' equity